Precision Radiation Oncology最新文献_第2页

Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy. 革命性的癌症治疗：放射性药物在现代癌症治疗中的作用。

Precision Radiation Oncology Pub Date : 2024-09-11 eCollection Date: 2024-09-01 DOI: 10.1002/pro6.1239

Treesa P Varghese, Anish John, Jithin Mathew

{"title":"Revolutionizing cancer treatment: The role of radiopharmaceuticals in modern cancer therapy.","authors":"Treesa P Varghese, Anish John, Jithin Mathew","doi":"10.1002/pro6.1239","DOIUrl":"https://doi.org/10.1002/pro6.1239","url":null,"abstract":"Radiopharmaceutical therapy (RPT) is a precision medicine approach that involves the targeted delivery of radioactive atoms to tumor cells, representing a breakthrough strategy for cancer treatment. Radiopharmaceuticals typically consist of a small amount of radioactive material, a radionuclide, paired with a chemical that specifically targets the cell. Some radionuclides naturally target specific cells or biological processes without the need for modification. RPT is a novel cancer treatment method that offers various advantages over current traditional treatment approaches. One of the primary advantages of RPT is its ability to target cancer cells, including those in metastatic areas. Another key advantage of RPT is that radiation can be delivered systemically, locally, or physiologically to specific cells internally rather than being applied externally. Moreover, radiotracer imaging can be utilized to determine radiopharmaceutical absorption in target tissues before providing a therapeutic dose. Compared to all other cancer treatment approaches, RPT has demonstrated high efficacy with minimal toxicity. The recent approval of multiple RPT medicines by the US Food and Drug Administration highlights the tremendous potential of this treatment. This article provides a detailed review of RPT, including insights into manufacturing procedures, safety measures, and its applications in cancer therapy.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 3","pages":"145-152"},"PeriodicalIF":0.0,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144019486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

NUT carcinoma of the head and neck: A case report and literature review. 头颈部NUT癌1例报告及文献复习。

Precision Radiation Oncology Pub Date : 2024-09-01 DOI: 10.1002/pro6.1237

Yue Zhao, Jun Zhang, Wenjun Liao, Jiayu Li, Shichuan Zhang

引用次数: 0

Clinical results of definitive radiotherapy for local recurrent kimura disease in the head and neck after surgery: A retrospective study. 头颈部局部复发木村病手术后放射治疗的临床结果：回顾性研究。

Precision Radiation Oncology Pub Date : 2024-08-21 eCollection Date: 2024-09-01 DOI: 10.1002/pro6.1238

Wenlong Lv, Shan Li, Feng Liu, Wangui Xue, Feibao Guo, Jinsheng Hong

{"title":"Clinical results of definitive radiotherapy for local recurrent kimura disease in the head and neck after surgery: A retrospective study.","authors":"Wenlong Lv, Shan Li, Feng Liu, Wangui Xue, Feibao Guo, Jinsheng Hong","doi":"10.1002/pro6.1238","DOIUrl":"https://doi.org/10.1002/pro6.1238","url":null,"abstract":"Objective: To evaluate the efficacy and safety of definitive radiotherapy in selected patients with local recurrence of Kimura disease of the head and neck after surgery.Methods: This retrospective study collected the clinical data of 14 patients with postoperative recurrence of Kimura disease of the head and neck who received definitive radiotherapy at the First Affiliated Hospital of Fujian Medical University between 2006 and 2022. The radiation dose ranged from 28 to 40 Gy. Its efficacy and safety were analyzed.Results: During follow-up, ranging from 17 to 168 months, local control was achieved in 13 (92.9%) of the 14 patients with postoperative recurrence. There were no serious late toxicities except for mild xerostomia in four (28.6%) patients; the patients' peripheral blood eosinophil count dropped from 1.73×109/L before treatment to 0.42×109/L after treatment, and the eosinophil percentage dropped from 20.64% to 9.78%. Both changes were statistically significant (p<0.001).Conclusions: The findings of the study suggest that definitive radiotherapy is a viable and effective alternative to repeated surgery for managing recurrent Kimura disease of the head and neck, with significant response rates and a good safety profile. Peripheral blood eosinophil counts and percentages serve as simple and reliable biomarkers for monitoring Kimura disease progression and treatment responses.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 3","pages":"119-125"},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating the method of selection of background pixel values for the calibration of EBT-XD film dosimetry. 探讨了EBT-XD薄膜剂量法标定时背景像素值的选择方法。

Precision Radiation Oncology Pub Date : 2024-08-11 eCollection Date: 2024-09-01 DOI: 10.1002/pro6.1236

Sathiya Raj, Nithya Shree, Ganesh Kadirampatti

{"title":"Investigating the method of selection of background pixel values for the calibration of EBT-XD film dosimetry.","authors":"Sathiya Raj, Nithya Shree, Ganesh Kadirampatti","doi":"10.1002/pro6.1236","DOIUrl":"https://doi.org/10.1002/pro6.1236","url":null,"abstract":"Purpose: This study investigates three different calibration methods for the selection of background pixel intensity.Methods: Film-by-Film (FBF) Method: Each film serves as its own control. Batch-by-Film (BBF) Method: A single film is used as a control for all calibration films. Generic (GEN) Method: A generic value (65535) is used as the background pixel value for all calibration films.Three calibration curves were established for the red, green, blue, and RGB channels, and the Radbard NIH (image) curve-fitting model was used to predict the dose. Sensitivity at different dose levels was quantified by calculating the first derivative of each color channel.Results: The GEN method exhibited a difference of up to 6% between the predicted and delivered doses below 2 Gy. The changes in optical density when using the GEN method differed significantly (p<0.0001) from those of the FBF and BBF methods. In the dose range 5-30 Gy, the percentage difference between the predicted and delivered doses for the FBF, BBF, and GEN methods was within 2%. Both the red and green channels demonstrated higher sensitivity than the blue channel over the dose range of 2-30 Gy.Conclusions: The FBF method is more accurate than the BBF and GEN methods because it accounts for inter-film variations. The Radbard NIH (image) curve-fitting function proved suitable for predicting the dose for all the three calibration methods.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 3","pages":"132-137"},"PeriodicalIF":0.0,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Sinonasal Teratocarcinosarcoma: A case report 鼻窦畸胎肉瘤的治疗：病例报告

Precision Radiation Oncology Pub Date : 2024-07-21 DOI: 10.1002/pro6.1235

Gang Yang, Xiaoshen Wang

引用次数: 0

Long-term survival after immunotherapy for uncontrolled locally advanced temporal bone squamous cell carcinoma followed by chemoradiotherapy: A case report. 不受控制的局部晚期颞骨鳞状细胞癌经放化疗后免疫治疗后的长期生存：1例报告。

Precision Radiation Oncology Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.1002/pro6.1233

Jin Yan, Jiangdong Sui

{"title":"Long-term survival after immunotherapy for uncontrolled locally advanced temporal bone squamous cell carcinoma followed by chemoradiotherapy: A case report.","authors":"Jin Yan, Jiangdong Sui","doi":"10.1002/pro6.1233","DOIUrl":"https://doi.org/10.1002/pro6.1233","url":null,"abstract":"Temporal bone squamous cell carcinoma (TBSCC) is a rare and invasive malignant tumor. The common predisposing factors include a history of local radiotherapy and chronic suppurative otitis media. The current treatment approach for TBSCC primarily involves surgery, followed by adjuvant radiotherapy and chemotherapy, based on T staging and high-risk factors. Although patients with early-stage TBSCC have a high survival rate after treatment, the majority of patients are diagnosed in the intermediate to advanced stages, with extensive tumor involvement, posing challenges for surgical intervention. Definitive chemoradiotherapy (CRT) serves as a viable alternative for unresectable tumors. Constraints in administering curative radiation doses, due to the tolerance of surrounding organs, can lead to uncontrolled tumor growth. Although programmed cell death 1 inhibitors have demonstrated efficacy in head and neck squamous cell carcinoma and cutaneous squamous cell carcinoma, their application in TBSCC remains underexplored. Herein, we report a case of a 47-year-old man diagnosed with unresectable advanced and localized TBSCC. Following inadequate tumor control with primary chemoradiotherapy, immunotherapy was initiated, resulting in disease remission within a follow-up period of > 4 years.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 2","pages":"99-105"},"PeriodicalIF":0.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935013/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analyzing the patient isocenter positional accuracy with portal imaging acquired at different gantry angles and its dosimetrical impact on the dose delivery for head and neck cancers. 分析病人等深点位置精度与门户成像获得的在不同的龙门角度及其dosimetrical影响剂量交付头部和颈部癌症的。

Precision Radiation Oncology Pub Date : 2024-06-28 eCollection Date: 2024-06-01 DOI: 10.1002/pro6.1234

Bharath Pandu, D Khanna, Mohandass Palanisamy, Saro Jacob, Tatarao Maddipati

{"title":"Analyzing the patient isocenter positional accuracy with portal imaging acquired at different gantry angles and its dosimetrical impact on the dose delivery for head and neck cancers.","authors":"Bharath Pandu, D Khanna, Mohandass Palanisamy, Saro Jacob, Tatarao Maddipati","doi":"10.1002/pro6.1234","DOIUrl":"https://doi.org/10.1002/pro6.1234","url":null,"abstract":"Objective: This study aimed to analyze the effect of different gantry angles on portal imaging in terms of isocenter shifts and their dosimetric impact on dose delivery.Methods: Thirty patients with head and neck cancers were prospectively selected for this study. The reference anterior to posterior (AP) digitally reconstructed reference radiograph image was obtained at a gantry angle of 0°. The AP portal images were acquired at angles of 0°, 0.5°, 1°, 1.5°, and 2.0°. The average deviation of the isocenter shift with respect to the zero-gantry angle was calculated. To check the dosimetric effects, the reference fluence was compared with different fluences measured at different isocenter shifts.Results: The average isocenter shift differences in the lateral direction were 0.7 mm, 1.3 mm, 1.9 mm, and 2.5 mm. The average difference was <±0.1 mm for isocenter shift in the longitudinal direction. The results of the statistical analysis showed that the average isocenter shift and gamma pass rate with respect to the different isocenter position errors were significant in the lateral direction.Conclusion: The results of this study showed that as the gantry angle increased, the isocenter shifted and the percentage of deviation in the lateral direction increased.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 2","pages":"77-84"},"PeriodicalIF":0.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current status and prospect of particle therapy for esophageal cancer. 食管癌颗粒治疗的现状与展望。

Precision Radiation Oncology Pub Date : 2024-06-27 eCollection Date: 2024-06-01 DOI: 10.1002/pro6.1232

Kang Wang, Shuanghu Yuan

{"title":"Current status and prospect of particle therapy for esophageal cancer.","authors":"Kang Wang, Shuanghu Yuan","doi":"10.1002/pro6.1232","DOIUrl":"https://doi.org/10.1002/pro6.1232","url":null,"abstract":"Esophageal cancer is among the top causes of cancer-related mortality worldwide, and the main treatment modality for locally advanced esophageal cancer is concurrent chemoradiotherapy. The current photon-based radiotherapy modalities and procedures have increased the incidence of treatment-related cardiac and pulmonary complications. Additionally, anatomical changes in the esophagus resulting from diaphragmatic movement, weight loss, and tumor progression present challenges for radiotherapy. These challenges have spurred interest in particle therapies, such as proton beam therapy (PBT) and heavy-ion therapy, for esophageal cancer. This paper comprehensively reviews the dosimetric advantages, clinical efficacy, and limitations of PBT and heavy-ion therapy for esophageal cancer and discusses their prospects. This highlights the unique dosimetric benefits of these therapies, particularly their ability to deliver high-dose radiation precisely to the tumor while sparing the surrounding normal organs and tissues. Although PBT and heavy-ion therapy demonstrate superior clinical efficacy compared to photon therapy, they are not without limitations. Multiple studies are needed to further validate and supplement the existing clinical and preclinical data to better exploit the benefits of PBT and thereby provide improved survival advantages to these patients.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 2","pages":"92-98"},"PeriodicalIF":0.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11935211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolution of dose distribution for a ¹²⁵I eye plaque using MCNPX and Plaque Simulator software. 使用MCNPX和斑块模拟器软件研究125I眼斑的剂量分布演变。

Precision Radiation Oncology Pub Date : 2024-06-16 eCollection Date: 2024-06-01 DOI: 10.1002/pro6.1231

Hosein Poorbaygi, Elham Sardari, Seyed Mahmoud Reza Aghamiri, Shahab Sheibani, Mojtaba Arjmand, Somayeh Moradi, Fariba Ghassemi

{"title":"Evolution of dose distribution for a 125I eye plaque using MCNPX and Plaque Simulator software.","authors":"Hosein Poorbaygi, Elham Sardari, Seyed Mahmoud Reza Aghamiri, Shahab Sheibani, Mojtaba Arjmand, Somayeh Moradi, Fariba Ghassemi","doi":"10.1002/pro6.1231","DOIUrl":"https://doi.org/10.1002/pro6.1231","url":null,"abstract":"Objective: Eye plaque radiation therapy is the treatment of choice for small- and medium-sized choroidal melanomas. This study investigated the dose distribution around eye plaques containing 125I seeds to treat ocular melanoma using Monte Carlo N-Particle eXtended (MCNPX) and Plaque Simulator (PS) software.Methods: Dosimetry evaluation and comparison of the resulting isodose curves for 125I COMS plaques were performed using the MCNPX code. The isodose curves and dose distributions were calculated using PS treatment planning for a 125I COMS plaque.Results: In the validation, the maximum relative difference between the results of this study and those reported in other literature was approximately 9%-10% for the COMS plaques. The dose distributions of MCNPX were lower than those of PS with a relative difference of approximately 27.7%-35.4%. The dose distribution may differ depending on the 125I source spectra and seed design used in the two methods. In addition, the dose algorithm used in PS made a major contribution to the relative differences between the results.Conclusion: The PS did not provide accurate details of dose distribution near the surface of the plaque insert. The source parameters used in each program should be studied more carefully to determine the source of the differences in the estimated dose values.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":"8 2","pages":"70-76"},"PeriodicalIF":0.0,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11934971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs 立体定向体放射治疗攻克肺转移灶：最新突破

Precision Radiation Oncology Pub Date : 2024-05-09 DOI: 10.1002/pro6.1226

Xin Liu, Lei Wu, Tian Guo, Zhifeng Huang, Sen Chen, ChenYang Li, Qiufang Liu, Fenggang Wang

{"title":"Stereotactic body radiotherapy takes on Lung Oligometastases: Latest breakthroughs","authors":"Xin Liu, Lei Wu, Tian Guo, Zhifeng Huang, Sen Chen, ChenYang Li, Qiufang Liu, Fenggang Wang","doi":"10.1002/pro6.1226","DOIUrl":"https://doi.org/10.1002/pro6.1226","url":null,"abstract":"Lung oligometastases represent an intermediate state of cancer dissemination between localized and widespread metastases. Stereotactic body radiation therapy (SBRT) has emerged as an effective treatment option, with an efficacy comparable to that of surgical resection. This review aimed to provide a comprehensive summary of the latest advancements and controversial issues regarding SBRT for lung oligometastases. It focuses on four crucial perspectives: efficacy of SBRT, optimal patient selection criteria, technological innovations, and synergistic effects of SBRT combined with systemic therapy. Relevant clinical trials investigating SBRT for lung oligometastases have been conducted, with median 1‐ and 5‐year local control rates of 90% and 79%, respectively. The origin of the primary tumor, size and number of lesions, and biomarker profiles were highlighted as pivotal considerations in patient selection. The precise dose delivery was enhanced using robotic SBRT and optimized dose fractionation schemes. Evidence suggests that dose escalation above 100 Gy biologically effective dose may improve tumor control. Combined immunotherapy and SBRT have demonstrated synergistic effects in prolonging progression‐free survival and overall survival. This review provides valuable insights into the precise treatment of oligometastatic lung diseases using SBRT. Further multicenter randomized trials are warranted to develop definitive patient selection criteria and optimize the integration with systemic therapies.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":" 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140994736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0